FAQ on Lantern Pharma's Appointment of Dr. Lee T. Schalop to Its Board and Its AI-Driven Precision Oncology Efforts

Who has Lantern Pharma appointed to its Board of Directors?

Lantern Pharma has appointed Dr. Lee T. Schalop, co-founder and former CEO of Oncoceutics Inc., to its Board of Directors.

What expertise does Dr. Schalop bring to Lantern Pharma?

Dr. Schalop brings over 20 years of experience in biotechnology leadership and financial markets, with a focus on developing targeted therapies for solid tumors, including HK327M-mutant gliomas.

Why is Dr. Schalop’s appointment significant for Lantern Pharma?

His expertise in neurooncology and strategic transactions aligns with Lantern’s AI-powered drug development platform and its CNS cancer pipeline, potentially accelerating the development of novel therapies.

What is Lantern Pharma’s focus?

Lantern Pharma is a clinical-stage biopharmaceutical company that leverages artificial intelligence and genomic data to accelerate oncology drug discovery and development.

What is RADR(R), and how does it contribute to Lantern Pharma’s mission?

RADR(R) is Lantern Pharma’s proprietary AI and machine learning platform that leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to solve real-world problems in oncology drug development.

How quickly can Lantern Pharma advance its drug programs from AI insights to clinical trials?

On average, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program.

Where can I find more information about Lantern Pharma and its latest updates?

The latest news and updates relating to Lantern Pharma (LTRN) are available in the company’s newsroom at https://ibn.fm/LTRN.

What was Dr. Schalop’s previous achievement before joining Lantern Pharma?

Before joining Lantern Pharma, Dr. Schalop co-founded Oncoceutics Inc., which was acquired by Chimerix Inc. for $450 million in 2021 and later by Jazz Pharmaceuticals for $935 million in April 2025.